Search research articles
Contact Us
Filters
Showing results (61-70 of 76) with videos related to
Page
of 8
Sort By:
American Journal of Clinical Dermatology
|
July 20, 2022
Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis
Jonathan I Silverberg, David N Adam, Matthew Zirwas, et al.
Journal of the American Academy of Dermatology
|
July 25, 2024
Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
Brett King, Maryanne M Senna, Natasha A Mesinkovska, et al.
Dermatology and Therapy
|
February 5, 2026
Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND
Andrew Blauvelt, H Chih-Ho Hong, Norito Katoh, et al.
Journal of the American Academy of Dermatology
|
February 18, 2021
Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)
Eric L Simpson, Seth Forman, Jonathan I Silverberg, et al.
Dermatitis : Contact, Atopic, Occupational, Drug
|
September 21, 2016
The Association of Race/Ethnicity and Patch Test Results: North American Contact Dermatitis Group, 1998-2006
Vincent Anthony Deleo, Andrew Alexis, Erin M Warshaw, et al.
Journal of Drugs in Dermatology : JDD
|
February 6, 2023
The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Phase 2 Proof of Concept Study
Melinda Gooderham, Leon Kircik, Matthew Zirwas, et al.
Dermatitis : Contact, Atopic, Occupational, Drug
|
November 22, 2012
Effects of immunomodulatory agents on patch testing: expert opinion 2012
Joseph F Fowler, Howard I Maibach, Matthew Zirwas, et al.
Dermatitis : Contact, Atopic, Occupational, Drug
|
January 24, 2013
North American Contact Dermatitis Group patch test results for 2007-2008
Anthony F Fransway, Kathryn A Zug, Donald V Belsito, et al.
The Journal of Dermatological Treatment
|
June 11, 2026
Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summary
Andrew Blauvelt, Zoe D Draelos, Linda Stein Gold, et al.
The British Journal of Dermatology
|
June 6, 2023
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study
Leon H Kircik, Javier Alonso-Llamazares, Neal Bhatia, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 76) with videos related to
Sort By:
Page
of 8
American Journal of Clinical Dermatology
|
July 20, 2022
Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis
Jonathan I Silverberg, David N Adam, Matthew Zirwas, et al.
Journal of the American Academy of Dermatology
|
July 25, 2024
Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
Brett King, Maryanne M Senna, Natasha A Mesinkovska, et al.
Dermatology and Therapy
|
February 5, 2026
Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND
Andrew Blauvelt, H Chih-Ho Hong, Norito Katoh, et al.
Journal of the American Academy of Dermatology
|
February 18, 2021
Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)
Eric L Simpson, Seth Forman, Jonathan I Silverberg, et al.
Dermatitis : Contact, Atopic, Occupational, Drug
|
September 21, 2016
The Association of Race/Ethnicity and Patch Test Results: North American Contact Dermatitis Group, 1998-2006
Vincent Anthony Deleo, Andrew Alexis, Erin M Warshaw, et al.
Journal of Drugs in Dermatology : JDD
|
February 6, 2023
The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Phase 2 Proof of Concept Study
Melinda Gooderham, Leon Kircik, Matthew Zirwas, et al.
Dermatitis : Contact, Atopic, Occupational, Drug
|
November 22, 2012
Effects of immunomodulatory agents on patch testing: expert opinion 2012
Joseph F Fowler, Howard I Maibach, Matthew Zirwas, et al.
Dermatitis : Contact, Atopic, Occupational, Drug
|
January 24, 2013
North American Contact Dermatitis Group patch test results for 2007-2008
Anthony F Fransway, Kathryn A Zug, Donald V Belsito, et al.
The Journal of Dermatological Treatment
|
June 11, 2026
Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summary
Andrew Blauvelt, Zoe D Draelos, Linda Stein Gold, et al.
The British Journal of Dermatology
|
June 6, 2023
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study
Leon H Kircik, Javier Alonso-Llamazares, Neal Bhatia, et al.
Page
of 8